High parathyroid hormone (PTH) occurs when the parathyroid glands produce excessive amounts of this hormone, disrupting calcium balance in the blood and tissues. This condition often results in hypercalcemia, bone loss, and increased risk of kidney stones.
Parathyroid hormone is produced by four small glands located behind the thyroid gland in the neck. These glands regulate calcium and phosphate levels in the bloodstream through direct feedback with blood calcium concentrations. When blood calcium drops, PTH rises to stimulate calcium release from bones, increase calcium reabsorption in the kidneys, and activate vitamin D to improve intestinal calcium absorption.
When PTH remains consistently elevated, the body's calcium homeostasis system becomes dysregulated. This leads to chronic hypercalcemia, which can damage organs and weaken bones. High PTH is most commonly caused by benign tumors (adenomas) in one parathyroid gland, though multiple glands may be involved in rare cases.
The parathyroid glands monitor blood calcium levels continuously. A normal PTH level ranges between 10 and 65 pg/mL, depending on the lab. Levels above 65 pg/mL are considered elevated, especially when paired with high serum calcium.
Excess PTH increases osteoclast activity in bone tissue, breaking down bone matrix and releasing calcium into the bloodstream. Over time, this causes reduced bone mineral density, increasing fracture risk. In the kidneys, PTH enhances calcium reabsorption while promoting phosphate excretion. Chronic high PTH reduces renal tubular function and raises the risk of nephrolithiasis (kidney stones).
A 2021 study published in *The Journal of Clinical Endocrinology & Metabolism* found that patients with persistent high PTH had a 40% higher incidence of vertebral fractures compared to those with normal PTH, even when calcium levels were only mildly elevated.
High PTH falls into two main categories: primary and secondary hyperparathyroidism. Primary hyperparathyroidism results from intrinsic dysfunction of the parathyroid glands, usually due to a single adenoma. Secondary hyperparathyroidism arises from external factors that chronically lower blood calcium, such as vitamin D deficiency or chronic kidney disease.
| Type | Primary Cause | Blood Calcium | Blood Phosphate | Common Triggers |
|---|---|---|---|---|
| Primary | Parathyroid adenoma (95% of cases) | Elevated | Low | Spontaneous gland overactivity |
| Secondary | Chronic kidney disease, vitamin D deficiency | Normal or low | Low | Renal failure, malabsorption |
Teritary hyperparathyroidism develops in patients with long-standing secondary hyperparathyroidism, particularly those on dialysis. Here, the glands become autonomous and continue secreting PTH even when calcium levels normalize.
One non-obvious distinction: high PTH with normal calcium levels is not typical of primary hyperparathyroidism. This pattern suggests either early disease, mild forms, or secondary causes. A 2023 review in *Endocrine Reviews* emphasized that normal calcium with elevated PTH should prompt testing for vitamin D deficiency and kidney function.
High PTH is detected through blood tests measuring intact PTH (iPTH), serum calcium, and phosphate. A diagnostic algorithm typically includes:
Patients with high PTH often report fatigue, muscle weakness, depression, and frequent urination. Bone pain and fractures may occur silently. In severe cases, confusion, nausea, and cardiac arrhythmias arise from hypercalcemia.
I once observed a 58-year-old woman with unexplained fatigue and recurrent kidney stones. Her initial labs showed calcium at 10.8 mg/dL (normal: 8.5-10.2) and PTH at 120 pg/mL. A sestamibi scan revealed a 1.5 cm adenoma in the left inferior parathyroid gland. After surgical removal, her calcium normalized within 48 hours and symptoms resolved over six weeks.
High PTH is frequently mistaken for hypercalcemia itself. But the two are distinct: high PTH causes hypercalcemia, yet some people have elevated PTH with normal calcium. This is known as normocalcemic primary hyperparathyroidism and affects about 10% of diagnosed cases.
Another error is assuming all high PTH cases require surgery. Guidelines from the American Association of Clinical Endocrinologists (AACE) state that surgery is recommended for symptomatic patients or those with bone density T-scores below -2.5, serum calcium above 1 mg/dL above the upper limit of normal, or creatinine clearance under 60 mL/min.
Some patients confuse high PTH with hyperparathyroidism caused by malignancy. Paraneoplastic hypercalcemia due to cancer can mimic high PTH, but in those cases, PTH is suppressed, not elevated. Measuring PTH correctly differentiates between primary hyperparathyroidism and malignancy-related hypercalcemia.
Surgical removal of the affected parathyroid gland (parathyroidectomy) is the definitive treatment for primary hyperparathyroidism. Success rates exceed 95% in experienced centers. Minimally invasive techniques reduce recovery time and complications.
For patients who decline surgery or have contraindications, medical management includes bisphosphonates to slow bone loss and calcimimetics like cinacalcet, which lower PTH secretion by sensitizing calcium-sensing receptors in the parathyroid glands.
Monitoring involves annual blood tests for calcium, PTH, and kidney function. Patients should avoid thiazide diuretics, which can worsen hypercalcemia, and ensure adequate hydration to prevent kidney stone formation.
High parathyroid hormone is a treatable endocrine disorder with clear diagnostic markers and effective interventions. Early detection prevents irreversible organ damage and improves quality of life.